How Anti-Wrinkle Injections Actually Work

The short answer

Anti-wrinkle injections use a purified protein, given in tiny medical doses. When injected into a specific muscle, it temporarily blocks the chemical signal between nerve and muscle. The muscle stops contracting. Over 3 to 4 months, the nerve terminals regenerate and the muscle resumes normal function.

That is the entire mechanism. Everything else (choice of licensed product, dosing strategy, injection technique, treatment philosophy) is downstream of that single biological fact.

The mechanism, in detail

Every voluntary muscle in the body is controlled by motor nerves. When the brain signals a muscle to contract, the nerve terminal releases acetylcholine: a small molecule that crosses the gap between nerve and muscle (the neuromuscular junction) and triggers contraction.

The medicine used in anti-wrinkle injections works by cleaving SNARE proteins inside the nerve terminal. Without functional SNARE proteins, the nerve terminal cannot release acetylcholine. The signal stops at the nerve, the muscle does not receive it, and the muscle does not contract.

It does not damage the nerve itself. The nerve is still there, still alive, still firing: it is simply unable to deliver its message to the muscle. Over weeks, the nerve grows new collateral terminals that bypass the affected sites and re-establish communication. This nerve regeneration is what determines duration of effect, not how quickly the medicine itself is broken down (which actually happens faster).

The UK-licensed options

Several prescription products are licensed by the MHRA for use in the UK. They all contain the same active type-A protein, and they differ in three practical ways:

1. Formulation: some products ship the active protein alongside non-active accessory proteins that protect the molecule during storage; one removes these (a “naked” formulation). The theoretical advantage of the naked form is a lower risk of antibody formation over years of repeat treatment; in clinical practice this difference has been hard to demonstrate.
2. Unit conversion: one unit of one product is not the same as one unit of another. The conversion factor between product families is roughly 2.5 to 3×, so a practitioner switching between them must redo the dosing maths.
3. Onset and diffusion: some products diffuse slightly more than others, which can be useful in broad areas like the forehead and disadvantageous in precise areas like the lower eyelid. A skilled practitioner uses the diffusion characteristic strategically.

Dr Oli selects and prescribes the most appropriate licensed product for your specific anatomy, history, and treatment area, and explains the choice at consultation.

Where the product choice actually matters

The choice of product makes a meaningful difference in three situations:

• Patients with prior antibody formation: rare, but if a patient stops responding to one product, moving to the “naked” formulation is the standard next step.
• Medical indications: chronic migraine treatment under the PREEMPT protocol specifies a particular licensed product in its licensed indication; substituting an unlicensed product changes the regulatory and clinical picture.
• Specific anatomical areas: for very precise placement (e.g. lower-face fine-tuning), the lower-diffusion products are sometimes preferred.

For the majority of cosmetic upper-face treatments, the licensed products produce equivalent results when dosed correctly. Marketing claims that suggest otherwise rarely survive examination.

What actually determines your result

Far more important than which product is used:

• Anatomical assessment: does the practitioner understand which muscle is producing which line, in your face specifically? Forehead anatomy varies meaningfully between patients and a one-size-fits-all injection pattern produces uneven results.
• Dose: too little produces underwhelming results that wear off early; too much produces the frozen look. Conservative starting doses err on the low side because adding more product later is easy whereas waiting for excess to wear off takes months.
• Injection depth and placement: surface placement reduces diffusion to unintended muscles; deep placement targets specific muscle bellies. Both have their use cases.
• Timing of follow-up: a 2-week review allows residual asymmetry or under-treatment to be corrected before the result is fully settled.
• Practitioner experience: pattern-matching a difficult forehead, recognising eyelid ptosis risk anatomy, choosing where not to inject. These are judgements built over thousands of treatments.

What “natural-looking” actually means

The frozen, expressionless aesthetic associated with bad treatment is a dosing and placement problem, not a product problem. A practitioner who uses conservative doses, treats fewer muscles rather than more, and leaves some natural movement in the forehead can produce a result that no observer would identify as treated: using any of the licensed products.

The over-treated look comes from:

• Over-dosing the frontalis (forehead muscle) so the brow cannot lift
• Treating both depressor and elevator muscles indiscriminately, locking the brow in place
• Chasing every wrinkle rather than treating selectively
• Treating too frequently: repeat injections before the previous result has worn off cumulatively over-relax the muscles

Conservative practitioners use lower starting doses, fewer injection points, and longer intervals between treatments. The patient who looks rested rather than treated is the patient whose injector is using less product, not more.

Bottom line

The medicine used in anti-wrinkle injections is one of the most-studied, longest-used injectables in modern medicine. The mechanism is elegant and reversible: block the nerve signal, the muscle stops, the lines soften, the nerve regrows, the result fades, repeat if desired. The UK-licensed products are clinically equivalent for most aesthetic indications. The skill in the chair (anatomical knowledge, conservative dosing, honest consultation, willingness to decline treatment) matters more than the product on the trolley.

Frequently asked questions

How do anti-wrinkle injections actually relax a muscle?

The prescription medicine used is a protein that, when injected into a muscle, blocks the release of acetylcholine, the neurotransmitter that signals nerve to muscle to contract. Without the signal, the muscle stops contracting. New nerve terminals grow back over 3 to 4 months, at which point the muscle resumes normal function and a top-up treatment is needed if the patient wants to maintain the effect.

Are the different licensed products meaningfully different?

Several prescription products are licensed in the UK and share the same active type-A protein. They differ in formulation and in the unit-conversion factor used for dosing, so a practitioner switching products must redo the dosing maths. Head-to-head clinical data shows similar duration of effect (typically 3 to 4 months in the upper face) when dosed equivalently. The product matters less than the dose, placement, and practitioner.

How long do anti-wrinkle injections last?

Typically 3 to 4 months in the upper face. Duration is more strongly influenced by the patient's individual metabolism, the muscle group treated, and the dose used than by which licensed product is chosen. With consistent treatment the interval often stretches as the treated muscles become less active.

Are anti-wrinkle injections safe?

The prescription medicine used has been used in medicine since the 1970s (initially for strabismus, then for spasticity, blepharospasm, hyperhidrosis, chronic migraine, and from the late 1980s for aesthetic indications). It is one of the most-studied injectable medicines in modern practice. All UK-licensed products are prescription-only and must be prescribed by a doctor, dentist, or independent prescriber. Side effects are typically mild, such as bruising, pinpoint bleeds, and rare brow or eyelid drop in the first 2 weeks if the product diffuses to an unintended muscle.